Teva Pharmaceutical Industries Dirección
Dirección controles de criterios 2/4
El CEO de Teva Pharmaceutical Industries' es Richard Francis , nombrado en Jan 2023, tiene una permanencia de 1.25 años. compensación anual total es $25.71M, compuesta por 6.2% salario y 93.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.011% de las acciones de la empresa, por valor de $1.63M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 6.8 años, respectivamente.
Información clave
Richard Francis
Chief Executive Officer (CEO)
US$25.7m
Compensación total
| Porcentaje del salario del CEO | 6.2% |
| Permanencia del CEO | 1.3yrs |
| Participación del CEO | 0.01% |
| Permanencia media de la dirección | 2.5yrs |
| Promedio de permanencia en la Junta Directiva | 6.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26
Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis
Aug 29These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively
Aug 05Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg
Aug 03Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings
Jul 26Teva again in the sights of New York Attorney General over alleged role in opioid crisis
Jul 11Teva names new medical chief
Jul 01Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
Jun 203 Reasons To Buy Teva At $10
Apr 07Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet?
Mar 24Teva Pharmaceutical: Prepare For Takeoff
Feb 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$26m | US$2m | -US$559m |
Compensación vs. Mercado: La compensación total de Richard($USD25.71M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD13.51M).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Richard con los resultados de la empresa.
CEO
Richard Francis (55 yo)
1.3yrs
Permanencia
US$25,706,880
Compensación
Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 1.3yrs | US$25.71m | 0.011% $ 1.6m | |
| Executive VP & CFO | 4.3yrs | US$4.94m | 0.064% $ 9.6m | |
| Executive Vice President of Global Operations | 4.5yrs | US$4.25m | 0.035% $ 5.3m | |
| Executive Vice President of International Markets Commercial | 2.7yrs | US$3.73m | 0.028% $ 4.2m | |
| Executive Vice President of European Commercial | 6.4yrs | US$5.16m | 0.0087% $ 1.3m | |
| Senior VP & Chief Accounting Officer | 2.4yrs | sin datos | 0.0029% $ 441.2k | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Senior Vice President | 1.8yrs | sin datos | sin datos | |
| Executive VP & Chief Legal Officer | less than a year | sin datos | sin datos | |
| Acting Head of Global Human Resources | less than a year | sin datos | 0.0013% $ 201.1k | |
| Senior Vice President of Investor Relations | no data | sin datos | sin datos | |
| Senior VP & Chief Internal Auditor | 9.9yrs | sin datos | sin datos |
2.5yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de TEVA se considera experimentado (2.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | no data | US$25.71m | 0.011% $ 1.6m | |
| Independent Chairman of the Board | 9.3yrs | US$539.99k | 0.033% $ 4.9m | |
| Independent Director | 15.3yrs | US$340.00k | 0.18% $ 27.5m | |
| Independent Director | 8.6yrs | US$355.00k | 0.0075% $ 1.1m | |
| Independent Director | 6.8yrs | US$340.00k | 0.0066% $ 987.5k | |
| Independent Director | 8.6yrs | US$330.00k | 0.0073% $ 1.1m | |
| Independent Director | 3.8yrs | US$325.46k | 0.0038% $ 568.8k | |
| Independent Director | 2.5yrs | US$330.00k | 0.0025% $ 370.7k | |
| Independent Director | 6.8yrs | US$320.00k | 0.0066% $ 987.5k | |
| Independent Director | 5.8yrs | US$315.25k | 0.0059% $ 889.9k | |
| Independent Director | less than a year | US$176.66k | sin datos |
6.8yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de TEVA se considera experimentada (6.8 años de antigüedad promedio).